Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 18/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL501974 | 1.00 | NOTUM (0.39) | NOTUMMDM2CYP1A2 | |
| SCHEMBL501975 | 1.00 | NOTUM (0.39) | NOTUMMDM2CYP1A2 | |
| SCHEMBL20853553 | 0.96 | NOTUM (0.36) | NOTUMMDM2CYP1A2 | |
| SCHEMBL3835696 | 0.95 | NOTUM (0.41) | NOTUM | |
| SCHEMBL502154 | 0.95 | NOTUM (0.41) | NOTUM | |
| SCHEMBL3481434 | 0.95 | NOTUM (0.41) | NOTUM | |
| SCHEMBL502155 | 0.95 | NOTUM (0.41) | NOTUM | |
| SCHEMBL502501 | 0.94 | NOTUM (0.35) | NOTUMMDM2 | |
| SCHEMBL4255728 | 0.94 | NOTUM (0.35) | NOTUMMDM2 | |
| SCHEMBL502502 | 0.94 | NOTUM (0.35) | NOTUMMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7906652-B2 | Heterocycle-substituted 3-alkyl azetidine derivatives | MERCK SHARP & DOHME CORP. (US) | 2011-03-15 | — | — | US | disclosed |
| US-20100081642-A1 | CB-1 RECEPTOR MODULATOR PHARMACEUTICAL FORMULATIONS | MERCK SHARP & DOHME CORP. | 2010-04-01 | — | — | US | disclosed |
| EP-2083822-A2 | SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS | Merck & Co., Inc. (US) | 2009-08-05 | — | — | EP | disclosed |
| EP-2083831-A2 | METHOD OF TREATMENT USING FATTY ACID SYNTHESIS INHIBITORS | Merck & Co., Inc. (US) | 2009-08-05 | — | — | EP | disclosed |
| WO-2009048544-A1 | LIQUID PHARMACEUTICAL COMPOSITIONS FOR PARENTERAL ADMINISTRATION OF A SUBSTITUTED AMIDE | MERCK & CO., INC. (US) | 2009-04-16 | — | — | WO | disclosed |
| EP-2010519-A2 | SUBSTITUTED IMIDAZOLE 4-CARBOXAMIDES AS CHOLECYSTOKININ-1 RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2009-01-07 | — | — | EP | disclosed |
| EP-1940842-A2 | ACYLATED SPIROPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2008-07-09 | — | — | EP | disclosed |
| WO-2008051404-A2 | SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS | MERCK & CO., INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008039327-A2 | METHOD OF TREATMENT USING FATTY ACID SYNTHESIS INHIBITORS | MERCK & CO., INC. (US) | 2008-04-03 | — | — | WO | disclosed |
| WO-2007120655-A2 | SUBSTITUTED IMIDAZOLE 4-CARBOXAMIDES AS CHOLECYSTOKININ-1 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007041052-A2 | ACYLATED SPIROPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081642-A1 | CB-1 RECEPTOR MODULATOR PHARMACEUTICAL FORMULATIONS | CNR1, CNR2, GPBAR1 | NOTUM 1240/4885MDM2 3678/4885CYP1A2 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.